Iloprost
As of the edition of 20 October 2026, Iloprost is a small molecule: marketed, first approved in 1992 (FR); acts on PTGIR; no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Ventavis
- First approved
- 16 June 1992 (FR)
- Approvals on record
- 11 in 7 regions
- Holder of the most recent approval
- Btg; 4 holders in all
- Registered trials
- 77, 16 stopped early
- Disease areas
- Lungs and airways; Heart and blood vessels; Cancer; Infections; Inherited and neonatal; Blood and lymph
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Btg holds a later exclusivity on its own new formulation or combination product, ending 2031; it does not protect the original drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Iloprost.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGIR | Prostacyclin receptor | P43119 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 27 | 20 | 1 | 3 |
| Phase 1 | 5 | 3 | 0 | 1 |
| Phase 2 | 22 | 12 | 1 | 7 |
| Phase 3 | 15 | 10 | 1 | 2 |
| Phase 4 | 8 | 2 | 1 | 3 |
| All trials | 77 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Applicant and Lead sponsor of trials | 1992 to now |
| Johnson & Johnson | Acquired holder and Lead sponsor of trials | 2004 to now |
| Btg | Acquired holder | 2024 to now |